DNA immunization using constant-current electroporation affords long-term protection from autochthonous mammary carcinomas in cancer-prone transgenic mice
暂无分享,去创建一个
G. Forni | A. Amici | C. Curcio | F. Cavallo | M. Spadaro | R. Draghia‐Akli | G Forni | A S Khan | E. Quaglino | F Cavallo | A. Khan | A Amici | C Curcio | M Spadaro | E Quaglino | R Draghia-Akli | Federica Cavallo | G. Forni | Augusto Amici
[1] P. Musiani,et al. Analysis of mammary carcinoma onset and progression in HER-2/neu oncogene transgenic mice reveals a lobular origin. , 1999, Laboratory investigation; a journal of technical methods and pathology.
[2] M. Colombo,et al. Myeloid cell expansion elicited by the progression of spontaneous mammary carcinomas in c-erbB-2 transgenic BALB/c mice suppresses immune reactivity. , 2003, Blood.
[3] P. Musiani,et al. Down regulation of major histocompatibility complex class I expression in mammary carcinoma of HER‐2/neu transgenic mice , 1998, International journal of cancer.
[4] Richard Heller,et al. In vivo electroporation for gene therapy. , 2006, Human gene therapy.
[5] Julie Gehl,et al. Electrochemotherapy: results of cancer treatment using enhanced delivery of bleomycin by electroporation. , 2003, Cancer treatment reviews.
[6] J. Grob,et al. Randomized Controlled Study of Electrochemotherapy in the Local Treatment of Skin Metastases of Melanoma , 2006, Journal of cutaneous medicine and surgery.
[7] M. Fiorotto,et al. A new plasmid-mediated approach to supplement somatotropin production in pigs. , 2004, Journal of animal science.
[8] L. Babiuk,et al. Electroporation improves the efficacy of DNA vaccines in large animals. , 2002, Vaccine.
[9] Piero Musiani,et al. Cure of Mammary Carcinomas in Her-2 Transgenic Mice through Sequential Stimulation of Innate (Neoadjuvant Interleukin-12) and Adaptive (DNA Vaccine Electroporation) Immunity , 2005, Clinical Cancer Research.
[10] R. Draghia‐Akli,et al. Successful parallel development and integration of a plasmid-based biologic, container/closure system and electrokinetic delivery device. , 2006, Vaccine.
[11] G. Forni,et al. Distinct and Non-Overlapping T Cell Receptor Repertoires Expanded by DNA Vaccination in Wild-Type and HER-2 Transgenic BALB/c Mice1 , 2006, The Journal of Immunology.
[12] G. Ciliberto,et al. Detection of integration of plasmid DNA into host genomic DNA following intramuscular injection and electroporation , 2004, Gene Therapy.
[13] Y. Glinka,et al. Electroporation-enhanced nonviral gene transfer for the prevention or treatment of immunological, endocrine and neoplastic diseases. , 2006, Current gene therapy.
[14] H. Ikeda,et al. Peptides derived from a wild-type murine proto-oncogene c-erbB-2/HER2/neu can induce CTL and tumor suppression in syngeneic hosts. , 1997, Journal of immunology.
[15] J. Roberts,et al. Dendritic cell elimination as an assay of cytotoxic T lymphocyte activity in vivo. , 2000, Journal of immunological methods.
[16] Piero Musiani,et al. Immunobiology of her-2/neu transgenic mice. , 2004, Breast disease.
[17] P. Musiani,et al. Immunosurveillance of Erbb2 carcinogenesis in transgenic mice is concealed by a dominant regulatory T-cell self-tolerance. , 2006, Cancer research.
[18] D. Coppola,et al. Electrically mediated delivery of vector plasmid DNA elicits an antitumor effect , 2002, Gene Therapy.
[19] P. Leder,et al. Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene , 1988, Cell.
[20] Federica Cavallo,et al. Vaccines for tumour prevention , 2006, Nature Reviews Cancer.
[21] R. Draghia‐Akli,et al. Highly efficient constant-current electroporation increases in vivo plasmid expression. , 2005, DNA and cell biology.
[22] E. Jaffee,et al. Identification and Characterization of the Immunodominant Rat HER-2/neu MHC Class I Epitope Presented by Spontaneous Mammary Tumors from HER-2/neu-Transgenic Mice1 , 2003, The Journal of Immunology.
[23] Piero Musiani,et al. Electroporated DNA vaccine clears away multifocal mammary carcinomas in her-2/neu transgenic mice. , 2004, Cancer research.
[24] W. Davis,et al. Immune-enhancing effects of growth hormone-releasing hormone delivered by plasmid injection and electroporation. , 2004, Molecular therapy : the journal of the American Society of Gene Therapy.
[25] S. H. van der Burg,et al. Vaccination for treatment and prevention of cancer in animal models. , 2006, Advances in immunology.
[26] A. Keating,et al. Electroporation for gene therapy. , 1995, Methods in molecular biology.
[27] L. Babiuk,et al. Increased gene expression and inflammatory cell infiltration caused by electroporation are both important for improving the efficacy of DNA vaccines. , 2004, Journal of biotechnology.
[28] M. Jaroszeski,et al. Electrochemotherapy: an emerging drug delivery method for the treatment of cancer. , 1997, Advanced drug delivery reviews.
[29] D. Scherman,et al. Gene therapy of collagen-induced arthritis by electrotransfer of human tumor necrosis factor-alpha soluble receptor I variants. , 2004, Human gene therapy.
[30] J. Berzofsky,et al. Early Role of CD4+ Th1 Cells and Antibodies in HER-2 Adenovirus Vaccine Protection against Autochthonous Mammary Carcinomas , 2005, The Journal of Immunology.
[31] G. Ciliberto,et al. Gene electro‐transfer of an improved erythropoietin plasmid in mice and non‐human primates , 2005, The journal of gene medicine.
[32] P. Musiani,et al. Carcinomas in Transgenic BALB / c Mice Carcinogenesis Than Transplantable p 185 More Effectively Inhibits DNA Vaccination Against Rat Her-2 / Neu Musiani and , 2000 .
[33] J. Wolchok,et al. DNA vaccines against cancer. , 2006, Hematology/oncology clinics of North America.